Address: Level 1, 16 Napier Close DEAKIN ACT 2600,Australia
Tel: (602) 6282 6888
Web: http://www.pharmacouncil.com.au/
The Pharmaceuticals Industry Council is the peak body for Australia’s pharmaceutical and biotechnology industries. It brings together the innovative, generic and biotechnology industries to represent a whole-of-sector approach to addressing opportunities and threats to investment in the sector.
The PIC was established in June 2006, following the three-year implementation of the Government-endorsed Pharmaceuticals Industry Action Agenda. The PIC aims to take forward the work of the PIAA, particularly to double Australia’s share of the global pharmaceuticals industry by 2012.
The biopharmaceuticals sector in Australia employs approximately 34 000 people, exports almost $4 billion worth of medicines annually and invests more than $752 million per year in research and development collaborations with local hospitals, universities and research organisations. The industry is a major innovative contributor to the economy, and one of the most R&D intensive industries in Australia.
Investment, Intellectual Propery Rights, Corporate-Governmental relations
Richard Day of the University of New South Wales, writing in the October 2023 edition of DIA’s Global Forum magazine, looks at updates to the health technology assessment (HTA) processes…
Shawview Consulting’s Brendan Shaw looks back on a sombre United Nations High Level Meeting on Universal Health Coverage in New York last month, as stakeholders reflected on the long road…
After last year’s acquisition of Vifor Pharma, the firm’s largest ever, opened new avenues for diversification, the ground-breaking approval of the Hemgenix gene therapy for Hemophilia B was an equally…
Shawview Consulting’s Brendan Shaw casts his eye over the increased industry focus on Environment, Social, and Governance (ESG) issues in recent years, urging pharma companies to deliver on their ESG promises…
Brendan Shaw looks ahead to the rest of 2023, identifying five key trends to watch out for in the healthcare and life sciences sector. With the worst of COVID-19 now…
CSL, Australia’s largest biopharma company, overcame the challenges of the pandemic-related decline in plasma collection and has since racked up wins such as the acquisition of Vifor, the largest in…
A roundup of some of the latest news from Australian pharma, including CSL’s unification of business units, a workers strike at Pfizer’s manufacturing plant, a new USD 173 million research…
Pharmaceutical policy issues played a major role in Australia’s recent national election. Shawview Consulting’s Brendan Shaw outlines the medicines issues that came under scrutiny during the campaign. It was the…
Writing in April edition of DIA’s Global Forum magazine, the University of New South Wales’s Richard Day looks at Australia’s National Medicines Policy (NMP) and how it is being reshaped…
Writing in the January edition of DIA’s Global Forum magazine, Julia Chan, David Liew, Jana Stojanova, and Chris McMaster of Austin Health, Melbourne and St. Vincent’s Hospital Sydney outline how…
In conversation in the November issue of DIA’s Global Forum magazine, Australian Pharmaceutical medical and scientific Professionals Association (APPA) Past President David Grolman highlights the contributions that Australia is already…
Regular PharmaBoardroom contributor Brendan Shaw outlines how his home country of Australia has so far successfully managed to avoid the worst of the COVID-19 pandemic, providing opportunities for the life…
See our Cookie Privacy Policy Here
